The Series A round led by BCM highlights the role of technology, pharmacy collaboration and patient access across the specialty medication journey
Specialty medication services are evolving beyond prescription fulfillment toward closer coordination among clinical care, pharmacy operations and patient support. Publicly available financing information shows that Valendo Health completed a $14.5 million Series A round on July 26, 2026. BCM Bruker Capital Management GmbH led the financing, with participation from RIKX Capital, A195 Capital, 49th Fund and individual investors James Watt and Christoph Janz.
Valendo Health is led by co-founder and Chief Executive Officer Ogi Kavazovic. The company focuses on helping independent community practices establish and operate medically integrated dispensing capabilities, allowing specialty pharmacy services to be delivered within a clinical environment patients already know. In contrast to processes in which an outside pharmacy handles the prescription separately, medically integrated dispensing is designed to connect physicians, pharmacists, care coordinators and patients through a more unified service pathway.
The significance of this model extends beyond medication delivery. Specialty therapies frequently involve prior authorization, financial assistance, fulfillment, patient follow-up and ongoing treatment management. Valendo Health brings these functions into a coordinated technology and service framework, while real-time analytics help clinics monitor dispensing operations and quality performance. The company also provides support from pharmacists and care coordinators, connecting the technology platform with day-to-day clinical workflows.
The round comprises six investors: BCM Bruker Capital Management GmbH, RIKX Capital, A195 Capital, 49th Fund, James Watt and Christoph Janz, with BCM serving as lead investor. For Valendo Health, the $14.5 million financing adds capital for continued business development and strengthens its capacity to advance specialty pharmacy digitization and in-clinic dispensing services.
From an industry perspective, the investment reflects growing attention to infrastructure that supports the full specialty medication journey. The ability to combine technology with pharmacy expertise, clinic workflows and effective patient communication will be an important factor in determining whether medically integrated dispensing models can scale successfully.
Valendo Health’s long-term mission is to make specialty medications more accessible and affordable while advancing a specialty pharmacy experience that is more local, trusted and cost-effective. The Series A financing provides new capital support for that objective. The available financing information does not disclose the company’s valuation or a detailed breakdown of how the proceeds will be allocated.